Jump to Navigation
Trends and Sentiments
Comments and Analysis
Toyota Taps First Foreign Vice President
Clinton paves way for White House run
Healthcare law’s future hangs on a phrase
Uber invests in mapping software with deCarta acquisition
Budget housing for Houses of Parliament?
Rio Tinto: Attractive And Sustainable Dividend
Dividend Growth Stocks Are My Conviction
Fleetmatics Has Consistent Operations That Haven't...
Meritor: A Long Candidate On Margin Improvements And...
Zeltiq Aesthetics' (ZLTQ) CEO Mark Foley on Q4 2014...
Technology Leads Week With 5 IPO filings; 5 More Added To Calendar
8 U.S. IPOs Planned For The Week
IPO Preview: Cempra Holdings
2 Life Sciences IPOs Debut Below Target
Caesars Stands Out In A Busy IPO Week With Strong Returns
Trius Therapeutics: The Calm Before The Storm
2012 Biotech IPOs: Age Of The Dreamers?
2 Promising Biopharma Companies To Examine
Stephen Brozak: Changing The Way Money Is Made And Diseases Are Cured
Companies That Can Mend The Biotech Market: Stephen Brozak
Cempra's CEO Discusses Q1 2013 Results - Earnings Call Transcript
Cempra Management Discusses Toyama Exclusive Agreement Conference (Transcript)
Cempra's CEO Presents at BARDA Contract Award Conference (Transcript)
Can Cempra Beat The Superbugs?
Cempra's Platform Potentially Worth Billions In Battling Superbugs And MRSA
Cempra's CEO Discusses Q2 2013 Results - Earnings Call Transcript
Cempra's CEO Discusses Q3 2013 Results - Earnings Call Transcript
This Antibiotic Play May Be The Trius Of 2014
Cempra Holdings Hosts Solithromycin and Taksta Clinical Update Conference Call (Transcript)
Do Away With The Pill-A-Day Biotech Model: Steve Brozak
Cempra: Safety Results Solidifying Market Position
Cempra's CEO Discusses Q4 2013 Results - Earnings Call Transcript
Promising Biotechs Target New Ways To Kill Bad Bugs: Venture Capitalist Dennis Purcell
Cempra's CEO Discusses Q1 2014 Results - Earnings Call Transcript
A controversial low-cost eBike has now raised...
A man was found hiding in the cockpit of a...
EUR/GBP: 1.3744 USD/EUR: 1.1165 JPY/USD: 119.749
Bullfax.com - Market News & Analysis 2008-2011
Terms & Conditions